Research article summary (published 30 Dec 2004):

Prospective clinical trials of biotherapies in solid tumors: a 5-year survey.

Full Abstract

PURPOSE: To review the content and quality of prospective clinical trials of biotherapies in solid tumors. METHODS: Data were collected from the literature between 1990 and 2002 on general study characteristics, patient and disease factors, study methodology, and factors related to completeness of reporting. Quality of phase II studies was evaluated by an ad hoc questionnaire. Descriptive statistics, contingency tables, and the chi-square test were applied. RESULTS: A total of 334 studies were selected, of which about three quarters were multicenter, with 42.5% reporting phase I, 42.2% phase II or I/II, and 11.9% phase III or II/III studies. Only 13.7% were randomized, and a study design emphasizing statistical analysis was lacking in as many as one third. The assessment of biological endpoints was stated as the primary or secondary goal in half of these studies. Melanoma (17.1%), renal carcinoma (11.1%), gastrointestinal neoplasms (11.1%), and lymphomas (6.3%) were the most studied diseases. Immunotherapies accounted for 182 studies; the remaining 152 reported other biotherapies. Patients with (1) advanced disease (P = 0.003), (2) heavily pretreated neoplasms (P < 0.0001), (3) poor performance status (PS < 2) (P < 0.0001), were more frequently enrolled in studies of biotherapy. Biotherapies were less frequently evaluated in phase III studies (7/152) compared with immunotherapies (33/182) (P < 0.0001). A statistical study design was more frequently identified in biotherapy trials (127/152) compared with immunotherapy trials (98/182) (P < 0.0001). Biological endpoints were less frequently evaluated in phase III studies in both biotherapies (100% no vs 0% yes) and immunotherapies (81.8% no vs 18.2% yes) (P = 0.01, for biotherapies; P < 0.0001, for immunotherapies). Phase I immunotherapy studies more frequently applied biological or molecular criteria for patient selection (41.1%) than phase II (29.3%) and III (3.1%) studies (P < 0.0001). CONCLUSIONS: The very wide diversity in modalities of conducting and reporting clinical trials of biotherapies of solid tumors and the presence of some methodological pitfalls suggest that the methodological standards for conducting and publishing clinical trials in biotherapies should be improved to enhance the reliability of the body of published data.

Author information

Author/s: Ottaiano, Alessandro (A); Mollo, Ernesto (E); Di Lorenzo, Giuseppe (G); Pisano, Carmela (C); Di Maio, Massimo (M); Barletta, Emiddio (E); Pensabene, Matilde (M); Segati, Romana (R); Bullian, Pierluigi (P); Nasti, Guglielmo (G); Bryce, Jane (J); Scala, Stefania (S); Castello, Giuseppe (G); Ascierto, Paolo Antonio (PA);

Affiliation: Department of Medical Oncology, ULSS2, Santa Maria del Prato Hospital, via Bagnols Ceze, Feltre (BL), Italy. ale.otto(-atsign-)libero.it

Journal and publication information

Publication Type: Journal Article; Research Support, Non-U.S. Gov't; Review

Journal: Cancer immunology, immunotherapy : CII (Cancer Immunol Immunother), published in Germany. (Language: eng)

Reference: 2005-Jan; vol 54 (issue 1) : pp 44-50

Dates: Created 2005/02/04; Completed 2005/02/17; Revised 2007/11/15;

PMID: 15693138, status: MEDLINE (last retrieval date: 2/18/2009, IMS Date: )

Sourced from the National Library of Medicine. Abstract text and other information may be subject to copyright.

External Links for this article
(including full text providers, if available):

Click Electronic Full-text Provider Links to see options for finding the electronic full text links to this article. Note there may be a subscription or fee required for access to the full text. See our FAQ for information on finding FREE full text articles.

This article may also be located in paper journal collections available in many libraries. Use the Journal and Publication Information above to find the full article.

MeSH headings (categories)

This article was linked to the MESH Headings shown below.

Antineoplastic Combined Chemotherapy Protocols - therapeutic use Clinical Trials as Topic - statistics & numerical data Clinical Trials, Phase I as Topic - statistics & numerical data Clinical Trials, Phase II as Topic - statistics & numerical data Clinical Trials, Phase III as Topic - statistics & numerical data Humans

Immunotherapy - statistics & numerical data Neoplasms - therapy Patient Selection Prospective Studies Randomized Controlled Trials as Topic Retrospective Studies

Related articles

These are the highest related articles currently in the database:

• [Evaluation of efficacy and safety of intrabronchial specific immunotherapy with allergy medication against allergies to house mites among patients with bronchial asthma] 29 Apr 1999
• [Impact of immunochemotherapy on survival of patients with metastatic renal cell carcinoma. A retrospective study comparing interferon-alpha-2a/vinblastine versus interferon-alpha-2a/interleukin-2/5-fluorouracil] 30 Aug 2004
• Immunotherapeutics for nosocomial infections. 30 May 2004
• Hematotoxicity of interleukin-2 in man: clinical effects and comparison of various treatment regimens. 30 Dec 1992
• Systemic reactions to immunotherapy: the American Academy of Otolaryngic Allergy morbidity and mortality survey. 30 May 1994
• An indicator quantitatively comparing two treatment effect sizes on responder and non-responder groups--exponential of estimated interaction parameter. 29 Sep 1995
• Long-term efficacy of interferon-alpha in chronic inflammatory demyelinating polyneuropathy. 30 May 2002
• Vaccinations and steroids in MS: effects on disease progression and mood. 29 Jun 1999
• Quantitative assessment of the compliance with once-daily sublingual immunotherapy in children. 30 Oct 2007
• A multicenter trial of specific local nasal immunotherapy. 30 Dec 1999

See 100+ related articles.

Related Article Map

Legend: - FREE Full text Article. - Abstract only. - Title only. More help.

See a large map of 100+ related articles.